Aurobindo Pharma Ltd has received final approval for Nevirapine tablets and oral suspension from the US Food and Drug Administration.
The tablets are indicated for the treatment of human immunodeficiency virus (HIV) and were the generic version of Boehringer Ingelheim Pharmaceutical Inc’s Viramune tablets and oral suspension, the Hyderabad-based company said in a release.
The product, being manufactured at Aurobindo’s Hyderabad facility, would soon be launched in the US market.
According to IMS data, the products had a market size of $125 million for the twelve months ended December, 2011.